Stefan Knapp

Stefan Knapp

SGC Frankfurt

Knapp

Biography

Prof Stefan Knapp studied Chemistry at the University of Marburg (Germany) and at the University of Illinois (USA). He did his PhD in protein crystallography at the Karolinska Institute in Stockholm (Sweden) (1996) and continued his career at the Karolinska Institute as a postdoctoral scientist (1996-1999). In 1999, he joined the Pharmacia Corporation as a principal research scientist in structural biology and biophysics. He left the company in 2004 to set up a research group at the Structural Genomics Consortium at Oxford University (SGC). From 2008 to 2015 he was a Professor of Structural Biology at the Nuffield Department of Clinical Medicine (NDM) at Oxford University (UK) and between 2012 and 2015 he was the Director for Chemical Biology at the Target Discovery Institute (TDI). He joined Frankfurt University (Germany) in 2015 as a Professor of Pharmaceutical Chemistry and the Buchmann Institute of Molecular Life Sciences. He remains associated to the SGC as a visiting Professor at Oxford and he is also adjunct Professor of the George Washington University. Since 2017 he is the CSO of the newly founded SGC node at the Goethe-University Frankfurt. His research interests are the rational design of selective inhibitors that target protein kinases as well as protein interactions modules that function as reader domains of the epigenetic code.

Research Areas

My laboratory is interested in understanding molecular mechanisms that regulate protein function of key signalling molecules and how these mechanisms can be utilized for the development of highly selective and potent inhibitors (chemical probes). As a basis for this work we have generated a comprehensive set of high resolution crystal structures that cover most members of the protein family of interest. We are particularly interested in protein interactions module of the bromodomain family that specifically recognize ε-N-lysine acetylation motifs, a key event in the reading process of epigenetic marks. This effort generated several highly selective chemical probes targeting bromodomains. A second research focus is on protein kinases. Our laboratory has solved a comprehensive set of crystal structure of this large protein family offering the opportunity to understand molecular mechanisms of their regulation and developing new strategies for their selective targeting. We developed for example a number of highly selective inhibitors by exploring unusual binding modes and allosteric binding sites. A particular focus of the laboratory is also to understand structural mechanisms leading to slow binding kinetics as part of the K4DD consortium.

2010

Selective inhibition of BET bromodomains.

Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, Cameron MJ, Schwartz B, Heightman TD, La Thangue N, French CA, Wiest O, Kung AL, Knapp S, Bradner JE

Nature. 2010-12-23 . 468(7327):1067-73 .doi: 10.1038/nature09504

PMID: 20871596

Structural genomics of histone tail recognition.

Wang M, Mok MW, Harper H, Lee WH, Min J, Knapp S, Oppermann U, Marsden B, Schapira M

Bioinformatics. 2010-10-15 . 26(20):2629-30 .doi: 10.1093/bioinformatics/btq491

PMID: 20739309

Structural comparison of human mammalian ste20-like kinases.

Record CJ, Chaikuad A, Rellos P, Das S, Pike AC, Fedorov O, Marsden BD, Knapp S, Lee WH

PLoS ONE. 2010-8-6 . 5(8):e11905 .doi: 10.1371/journal.pone.0011905

PMID: 20730082

Structure of the CaMKIIdelta/calmodulin complex reveals the molecular mechanism of CaMKII kinase activation.

Rellos P, Pike AC, Niesen FH, Salah E, Lee WH, von Delft F, Knapp S

PLoS Biol.. 2010-7-27 . 8(7):e1000426 .doi: 10.1371/journal.pbio.1000426

PMID: 20668654

Targeting kinases for the treatment of inflammatory diseases.

Müller S, Knapp S

Expert Opin Drug Discov. 2010-7-15 . 5(9):867-81 .doi: 10.1517/17460441.2010.504203

PMID: 22823261

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.

López-Ramos M, Prudent R, Moucadel V, Sautel CF, Barette C, Lafanechère L, Mouawad L, Grierson D, Schmidt F, Florent JC, Filippakopoulos P, Bullock AN, Knapp S, Reiser JB, Cochet C

FASEB J.. 2010-4-16 . 24(9):3171-85 .doi: 10.1096/fj.09-143743

PMID: 20400536

Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function.

Kwiatkowski N, Jelluma N, Filippakopoulos P, Soundararajan M, Manak MS, Kwon M, Choi HG, Sim T, Deveraux QL, Rottmann S, Pellman D, Shah JV, Kops GJ, Knapp S, Gray NS

Nat. Chem. Biol.. 2010-4-11 . 6(5):359-68 .doi: 10.1038/nchembio.345

PMID: 20383151

The (un)targeted cancer kinome.

Fedorov O, Müller S, Knapp S

Nat. Chem. Biol.. 2010-2-16 . 6(3):166-169 .doi: 10.1038/nchembio.297

PMID: 20154661

PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.

Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J

Haematologica. 2010-2-9 . 95(6):1004-15 .doi: 10.3324/haematol.2009.017079

PMID: 20145274

2009

Structure and functional characterization of the atypical human kinase haspin.

Eswaran J, Patnaik D, Filippakopoulos P, Wang F, Stein RL, Murray JW, Higgins JM, Knapp S

Proc. Natl. Acad. Sci. U.S.A.. 2009-12-1 . 106(48):20198-203 .doi: 10.1073/pnas.0901989106

PMID: 19918057